The Marlborough, Mass.-based company said the 2025 notes will be unsecured obligations of the company with guarantees by certain subsidiaries, with an expected closing date on Oct. 10.
Proceeds from the round will be used to retire the company’s remaining convertible notes, including through repurchases or redemptions, as they become callable in December this year and next March.
Hologic announced the offering earlier this week alongside $3 billion in financing from both a term loan and revolving credit facility, saying that funds raised are slated to help it in restructuring its finances.
Hologic said it initially borrowed $345 million against the new credit facility, and has terminated its previous $1 billion revolving facility.
Late last month, Hologic said it won expanded FDA 510(k) clearance for its subsidiary Cynosure’s SculpSure non-invasive body contouring laser, now cleared to treat the submental area.